ArticleNature2023
Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
24.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Acute epiglottitis caused by COVID-19: A systematic review.Biomolecules & biomedicine · 2023Pooled it
- Accurate measurement of longitudinal paramagnetic relaxation enhancement through division after subtraction.Magnetic resonance letters · 2027Article
- SARS-CoV-2 enhances lysosomal exocytosis and deacidifies lysosomes to facilitate viral release.mLife · 2026Article
- Reverse genetics approach for arteriviruses using circular polymerase extension reaction.Access microbiology · 2026Article
- Modeling the effects of routine screening for accidental lab-acquired infections on the risk of potential pandemic pathogen escape from high-biosafety research facilities.Frontiers in bioengineering and biotechnology · 2026Article
- SARS-CoV-2 enhances complement-mediated endothelial injury via the suppression of membrane complement regulatory proteins.Emerging microbes & infections · 2025Article
- Perspective Overview of Changing Population Immunity to COVID-19 in the Context of Infection, Vaccination, and Emerging SARS-CoV-2 Variants.Pathogens (Basel, Switzerland) · 2025Review
- A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023.Communications medicine · 2025Review
- Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.Journal of virology · 2025Article
- Pathways in the brain, heart and lung influenced by SARS-CoV-2 NSP6 and SARS-CoV-2 regulated miRNAs: an in silico study hinting cancer incidence.Cardio-oncology (London, England) · 2025Article
- Domain-Specific Impacts of Spike Protein Mutations on Infectivity and Antibody Escape in SARS-CoV-2 Omicron BA.1.Journal of microbiology and biotechnology · 2025Article
- Comprehensive Analysis of the Impact of Weight Loss Thresholds on Mouse Models of Fatal Viral Infection.Viruses · 2025Article
- Characterisation of a persistent SARS-CoV-2 infection lasting more than 750 days in a person living with HIV: a genomic analysis.The Lancet. Microbe · 2025Article
- A single mutation may contribute to accelerated evolution of SARS-CoV-2 toward Omicron.Nature communications · 2025Article
- Comparison of the pathogenicity of multiple SARS-CoV-2 variants in mouse models.Animal models and experimental medicine · 2025Article
- The NSP6-L260F substitution in SARS-CoV-2 BQ.1.1 and XBB.1.16 lineages compensates for the reduced viral polymerase activity caused by mutations in NSP13 and NSP14.Journal of virology · 2025Article
- A novel, covalent broad-spectrum inhibitor targeting human coronavirus MNature communications · 2025Article
- Impact of SARS-CoV-2 Variant NSP6 on Pathogenicity: Genetic Analysis and Cell Biology.Current issues in molecular biology · 2025Article
- The association of cycle threshold value with clinical features in patients infected with Omicron variant.Virus research · 2025Article
- Subtle Changes at the RBD/hACE2 Interface During SARS-CoV-2 Variant Evolution: A Molecular Dynamics Study.Biomolecules · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 6 institutions in 2 countries.
Da-Yuan Chen *Department of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1957-3330
Chue Vin Chin *Department of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Devin KenneyNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Alexander H TavaresDepartment of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Nazimuddin KhanDepartment of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Hasahn L ConwayDepartment of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7328-3521
GuanQun LiuFlorida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL, USA.ORCID http://orcid.org/0000-0003-2520-7625
Manish C ChoudharyBrigham and Women's Hospital, Boston, MA, USA.
Hans P GertjeNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Aoife K O'ConnellNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7027-4267
Scott AdamsNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1472-0223
Darrell N KottonCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9604-8476
Alexandra HerrmannInstitute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Armin EnsserInstitute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
John H ConnorNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8867-7256
Markus BosmannThe Pulmonary Center and Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2773-1033
Jonathan Z LiBrigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9914-9662
Michaela U GackFlorida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL, USA.ORCID http://orcid.org/0000-0002-2163-2598
Susan C BakerDepartment of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.ORCID http://orcid.org/0000-0001-6485-8143
Robert N KirchdoerferDepartment of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin-Madison, Madison, WI, USA.ORCID http://orcid.org/0000-0002-5974-2709
Yachana KatariaDepartment of Pathology and Laboratory Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Nicholas A CrosslandNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3873-9188
Florian DouamNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Mohsan SaeedDepartment of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. msaeed1@bu.edu.ORCID http://orcid.org/0000-0001-8505-7054
Boston University · USBrigham and Women's Hospital · USCleveland Clinic Florida · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DELoyola University Chicago · USUniversity of Wisconsin–Madison · US
Funding
Vectra Polaris Quantitative Pathology Imaging SystemS10OD030269 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2021 to 2021
$402kVentana Discovery Ultra Research Autostainer: an Ex+ Core serviceS10OD026983 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2019 to 2019
$207kNIH HHS S10 OD026983NIH HHS S10 OD030269
Abstract
The SARS-CoV-2 Omicron variant is more immune evasive and less virulent than other major viral variants that have so far been recognized
Indexed as
Coronavirus Nucleocapsid ProteinsCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusVirulenceVirulence FactorsAnimalsCell LineCOVID-19 VaccinesHumansImmune EvasionLungMiceMutationViral Nonstructural ProteinsVirus ReplicationCoronavirus Nucleocapsid ProteinsCOVID-19 VaccinesORF1ab polyprotein, SARS-CoV-2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Nonstructural ProteinsVirulence Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.